STEVEN SUGG: Open Payments
NPI 1750308193 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,281 in 58 payments from 14 companies in 2025. Trend: 2023 $1,392 · 2024 $1,613 · 2025 $1,281
Food & beverage: $1,281
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $278 |
| ABBVIE INC. | 19 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $207 |
| Vanda Pharmaceuticals Inc. | 4 | $135 |
| Axsome Therapeutics, Inc. | 3 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
Products named: REXULTI, VRAYLAR, CAPLYTA, FANAPT, Auvelity, TRINTELLIX, Qelbree, SPRAVATO.
Industry payments across AL — which companies pay providers there.
